AlphAIAlphAI — Financial news for AI agents
morningstar.comSEP 142 min read$CTMX

Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint

Contineum Therapeutics' shares fell 8.2% after hours, trading at $13.59, after its Phase 2 trial for a depression treatment missed the primary efficacy endpoint. The drug, licensed to Johnson & Johnson, was well-tolerated but did not meet its main goal. The company is still analyzing the data.

Original reporting
morningstar.com
Published Sep 14, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$CTMX
Bearish
high confidence
Mentioned
$CTMX · $CTNM
Relevance
8/10
AlphAI data visualization · based on morningstar.com
Decision brief

The 30-second read

$CTMXBearishHigh
01

Why it matters

The failure to meet the primary endpoint signals a setback for the company's pipeline and may delay further development milestones.

02

Market read

The news directly affects CTMX stock and may influence sentiment toward similar biotech stocks.

03

What to watch

Potential for a follow‑on trial design or partnership with Johnson & Johnson could mitigate short‑term pain.

Relevance 8/10Novelty 9/10Timing: after‑hours Monday

Background

Contineum Therapeutics is developing JNJ-5120/PIPE-307 under a global license with Johnson & Johnson. The Moonlight-1 Phase 2 trial aimed to treat depression.

Company-level read

Ticker impact

$CTMXBearishHigh confidence
Context

Phase 2 Moonlight-1 trial missed primary efficacy endpoint; shares fell 8.2% after hours.

Expected impact

Expect continued downside pressure, potential 5-10% decline over next few days.

Evidence & confidence

Clinical trial failures for early‑stage biotech typically trigger sell‑offs; no new safety concerns but efficacy shortfall undermines near‑term value.

Market effects

Sector

May weigh on other depression‑treatment biotech peers and raise caution on similar Phase 2 programs.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

If the trial shows safety and tolerability, the company could pivot to a different indication, offering a longer‑term upside.

Key entities

  • Company
    Contineum Therapeutics

    Biotech firm developing depression treatment.

  • Partner
    Johnson & Johnson

    Global licensee and developer of the drug.

Read at source← All news

Also covered by

3 outlets

Related articles

OCT 12
$CTNMHigh

Contineum Therapeutics Shares Surge 27% After Bristol Myers Squibb Reports Positive Phase 3 Trial Results

Contineum Therapeutics (CTNM) shares rose 27% premarket after Bristol Myers Squibb (BMY) reported positive Phase 3 trial results for a pulmonary fibrosis treatment targeting the same pathway as CTNM's lead drug, PIPE-791. BMY's trial met its primary endpoint, showing improved lung function. CTNM's stock was indicated at $16.99, up from $13.38. The results may impact CTNM's valuation, though its drug remains in Phase 2.

finance.yahoo.com2 min
OCT 12
MedAI 8/10

Why is Contineum Therapeutics stock surging today?

Contineum Therapeutics stock surged 21.1% after Bristol Myers Squibb's Phase 3 trial for admilparant in pulmonary fibrosis met its primary endpoint. Contineum's PIPE-791, an LPA1 antagonist, benefits from this validation. Analysts have Buy ratings with targets ranging from $20 to $24. The move is driven by company-specific news, not broader market trends.

investing.com2 min
OCT 12
$CTNMHighAI 8/10

Contineum Therapeutics stock surges on Bristol Myers trial win

Contineum Therapeutics (CTNM) shares rose 27% in pre-market trading after Bristol Myers Squibb's Phase 3 trial for admilparant in idiopathic pulmonary fibrosis met its primary endpoint. Contineum's PIPE-791 targets the same biological pathway. CTNM was indicated at $16.99, up from $13.38. Stifel previously noted the trial's importance for Contineum's valuation.

uk.investing.com1 min
SEP 25
$CTNMMedAI 8/10

J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?

Contineum Therapeutics (CTNM) and Johnson & Johnson (JNJ) reported that their depression drug, JNJ-5120/PIPE-307, failed to meet the primary endpoint in a Phase 2 trial. The drug showed no new safety issues but did not demonstrate the required efficacy in treating major depressive disorder. JNJ is analyzing additional data to determine the next steps for the program.

insidermonkey.com4 min